spacer
home > ict > autumn 2017 > expert knowledge
PUBLICATIONS
International Clinical Trials

Expert Knowledge

After the US and Europe, Japan is the most important
market for biopharmaceutical R&D companies. The
Japanese pharmaceutical industry is worth $81 billion
and the major global companies have well-established
marketing and R&D operations in the region. Demands
for effective pharma products in Japan are growing,
but the current government emphasis on reducing
rising healthcare expenditure in the face of a rapidly
ageing population has made the business environment
challenging for the industry.

Japan has a mature, developed pharma market that is very
sensitive with respect to research quality, as the medical
community is exclusive, hierarchical and conservative.
Only 34% of clinical research is conducted by non-Japanese
businesses. During the late 1990s, several global CROs
expanded their operations, setting up offices in Japan to
coordinate global multicentre clinical trials as a part of their
drug development support to multinational companies.
In doing so, they have adapted to the different clinical
research environment in Japan, which is more resource-
focused and, therefore, more expensive when compared to
clinical trials in other regions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mary Pan is Vice President of General Management and Business Development at ICON, Asia Pacific, where she is responsible for growing and enhancing ICON’s presence in the region. She has over 17 years of global pharma and clinical development expertise, with a strong track record in Asia through roles at Becton Dickinson, ClinTec International, Johnson & Johnson and Pfizer. Mary holds bachelor degrees in economics and psychology and a Master of Business Administration from Brown University, US, and also has a law degree from the University of Edinburgh, UK.
spacer
Mary Pan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera joins IPAC-RS as an Associate Member

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Nemera’s decision to join IPAC-RS is part of its commitment to advance science and innovation. Nemera is committed to enhancing better patient outcomes by seeking innovative solutions and contributing actively to discussions about the future of drug delivery devices. Its membership in IPAC-RS will facilitate this important commitment.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement